John Jared M, Sinclair Rodney D
Sinclair Dermatology, East Melbourne, Victoria, Australia.
Int J Dermatol. 2023 Feb;62(2):257-259. doi: 10.1111/ijd.16373. Epub 2022 Aug 14.
Topical minoxidil has been used for many years to treat adult alopecia, and there is growing evidence supporting the off-label use of low-dose oral minoxidil (LDOM). However, there is little data on its use in pediatrics, and there are no recommended treatment guidelines. Adverse events are of particular concern in this population. We retrospectively reviewed the medical records of 63 patients aged between 0 and 12 years from a specialist hair clinic who were treated with LDOM or sublingual minoxidil (SM) to evaluate its safety and tolerability. LDOM and SM were generally well-tolerated, with mild hypertrichosis being the most commonly reported adverse event. Further large-scale studies are warranted to determine the efficacy and optimum dosage of systemic minoxidil for alopecia in the pediatric population.
外用米诺地尔已被用于治疗成人脱发多年，并且越来越多的证据支持低剂量口服米诺地尔（LDOM）的非标签使用。然而，关于其在儿科使用的数据很少，并且没有推荐的治疗指南。在这一人群中，不良事件尤其令人担忧。我们回顾性地查阅了一家专业毛发诊所63例年龄在0至12岁之间接受LDOM或舌下含服米诺地尔（SM）治疗的患者的病历，以评估其安全性和耐受性。LDOM和SM总体耐受性良好，轻度多毛症是最常报告的不良事件。有必要进行进一步的大规模研究，以确定系统性米诺地尔治疗儿科人群脱发的疗效和最佳剂量。
